MMS22L and metastatic malignant neoplasm in the lymph nodes: In the present study, we found that low MMS22L expression, immunohistochemically stained and analysed semiquantitatively in ESCC samples, was a useful predictor of worse responses to NCRT and lymph node metastasis, and enhanced migration and resistance to 5-FU in the TE-1 cell line.